
TRDA
Entrada Therapeutics Inc.
$5.47
-$0.18(-3.19%)
53
Overall
80
Value
45
Tech
36
Quality
Market Cap
$213.39M
Volume
146.57K
52W Range
$4.93 - $21.79
Target Price
$18.50
Order:
Income Statement
Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|
REVENUE | ||||||
Total Revenue | -- | -- | $129.0M | $210.8M | ||
Total Revenue | -- | -- | $129.0M | $210.8M | ||
GROSS PROFIT | ||||||
Gross Profit | -- | -- | $129.0M | $210.8M | ||
OPERATING EXPENSES | ||||||
Operating Expenses | $51.1M | $97.2M | $132.2M | $163.8M | ||
Research & Development | $35.9M | $66.6M | $99.9M | $125.3M | ||
Research Expense | $35.9M | $66.6M | $99.9M | $125.3M | ||
Selling, General & Administrative | $15.2M | $30.6M | $32.3M | $38.5M | ||
General & Administrative Expenses | $15.2M | $30.6M | $32.3M | $38.5M | ||
Salaries & Wages | -- | -- | $13.1M | $17.9M | ||
Depreciation & Amortization | $1.1M | $1.9M | $2.8M | $3.8M | ||
Depreciation & Amortization | $1.1M | $1.9M | $2.8M | $3.8M | ||
Other Operating Expenses | $6.0M | $8.8M | $16.4M | $15.5M | ||
OPERATING INCOME | ||||||
Operating income | $-51.1M | $-97.2M | $-3.2M | $47.0M | ||
EBITDA | $-50.1M | $-95.4M | $14.9M | $70.3M | ||
NON-OPERATING ITEMS | ||||||
Net Non-Operating Interest Income/Expense | -- | $-2.6M | $-15.2M | -- | ||
Other Income/Expense | $31.0K | $-2.6M | -- | -- | ||
Other Special Charges | $-31.0K | $2.6M | -- | -- | ||
PRE-TAX INCOME | ||||||
EBIT | $-51.2M | $-97.2M | $12.0M | $66.5M | ||
Pre-Tax Income | $-51.2M | $-94.6M | $-3.2M | $47.0M | ||
INCOME TAX | ||||||
Tax Provision | -- | -- | $18.7M | $900.0K | ||
NET INCOME | ||||||
Net Income | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
Net Income (Continuing Operations) | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
Net Income (Discontinued Operations) | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
Net Income (Common Stockholders) | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
Normalized Income | -- | -- | -- | $46.5M | ||
TOTALS | ||||||
Total Expenses | $51.1M | $97.2M | $132.2M | $163.8M | ||
SHARE & EPS DATA | ||||||
Average Shares Outstanding | $6.3M | $31.3M | $33.1M | $37.3M | ||
Average Shares Outstanding (Diluted) | $6.3M | $31.3M | $33.1M | $39.0M | ||
Shares Outstanding | $31.3M | $33.1M | $38.0M | $37.6M | ||
Basic EPS | $-8.16 | $-3.02 | $-0.20 | $1.76 | ||
Basic EPS (Continuing Operations) | $-8.16 | $-3.02 | $-0.20 | $1.76 | ||
Diluted EPS | $-8.16 | $-3.02 | $-0.20 | $1.68 | ||
Diluted EPS (Continuing Operations) | $-8.16 | $-3.02 | $-0.20 | $1.68 | ||
OTHER METRICS | ||||||
Other Gand A | $15.2M | $30.6M | $32.3M | $38.5M |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | TRDA | $5.47 | -3.2% | 146.57K |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Entrada Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW